AMELIA ISLAND, Florida — A new intraoperative ketorolac delivery device has the potential to disrupt NSAID delivery in cataract surgery, according to a presenter here.
At Cataract Surgery: Telling It Like It Is, Kenneth J. Mandell, MD, PhD, CEO of LayerBio, shared early clinical results of the OcuRing-K ketorolac device.
The OcuRing-K is a bioerodible steroid-sparing implant that is affixed to the IOL haptic before implantation and elutes ketorolac for 2 weeks to control pain and inflammation following surgery, according to Mandell.
“The OcuRing-K has the potential to expand the